Status:
RECRUITING
Regression of Cervical Precancerous Lesions and Associated Risk Factors
Lead Sponsor:
General University Hospital, Prague
Conditions:
Cervix Uteri SIL
HPV
Eligibility:
FEMALE
18-40 years
Brief Summary
The aim of this study is to assess the extent of histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3); evaluate the proportion of patients who experience the normaliz...
Detailed Description
Introduction There are three grades of dysplasia of the cervix based on their severity (CIN 1-3). Most women with CIN 2 or CIN 3 (high-grade - HG lesions) are referred for conization due to the presum...
Eligibility Criteria
Inclusion
- squamocolumnar junction fully visualized
- bioptically verified CIN 2 or CIN 3
- age ≥ 18 years
- age ≤ 40 years
- informed consent
Exclusion
- squamocolumnar junction not fully visualized
- suspicion on glandular lesion
- suspicion on invasive cancer
- personal history of CIN 2, 3 or cerv. cancer
- gravidity
- HIV positivity
- immunosuppression
- impossible photographic documentation
Key Trial Info
Start Date :
September 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06147388
Start Date
September 1 2022
End Date
September 1 2027
Last Update
November 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General University Hospital
Prague, Czechia, 12800